Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, Japan.
Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Saito-Asagi, Ibaraki, Osaka, Japan.
Int Immunopharmacol. 2018 Aug;61:385-393. doi: 10.1016/j.intimp.2018.06.027. Epub 2018 Jun 23.
Infectious diseases are the second leading cause of death worldwide, suggesting that there is still a need for the development of new and improved strategies for combating pathogens effectively. Streptococcus pneumoniae is the most virulent bacteria causing pneumonia with high mortality, especially in children and the elderly. Because of the emergence of antibiotic resistance in S. pneumoniae, employing a serotype-independent mucosal vaccine would be the best approach to prevent and treat the diseases caused by S. pneumoniae. In this study, we have developed a pneumococcal nasal vaccine, consisting of pneumococcal surface protein A (PspA) and cationic liposomes composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and cholesteryl 3β-N-(dimethylaminoethyl)-carbamate (DC-chol) (DOTAP/DC-chol liposome). The efficiency of this cationic liposome-based PspA nasal vaccine was examined in a murine model of S. pneumoniae infection. Intranasal vaccination with PspA and DOTAP/DC-chol liposomes conferred protective immunity against lethal inhalation of S. pneumoniae, improving the survival rate of infected mice. Moreover, intranasal immunization with PspA and DOTAP/DC-chol liposomes not only induced the production of PspA-specific IgA and IgG by both mucosal and systemic compartments but also elicited PspA-specific Th17 responses, which play a pivotal role in controlling S. pneumoniae infection by host innate immune response. We further demonstrated that DOTAP/DC-chol liposomes enhanced PspA uptake by nasal dendritic cells (DCs), which might be a mechanism for the induction of protective immune responses to S. pneumoniae infection. These results show that DOTAP/DC-chol liposome would be an efficient mucosal vaccine system for a serotype-independent universal nasal vaccine against pneumococcal infection.
传染病是全球第二大致死原因,这表明仍需要开发新的、改进的策略来有效对抗病原体。肺炎链球菌是导致肺炎的最具毒性的细菌,死亡率很高,尤其是在儿童和老年人中。由于肺炎链球菌对抗生素的耐药性的出现,采用血清型非依赖性黏膜疫苗将是预防和治疗肺炎链球菌引起的疾病的最佳方法。在本研究中,我们开发了一种肺炎球菌鼻腔疫苗,由肺炎球菌表面蛋白 A(PspA)和由 1,2-二油酰基-3-三甲铵丙烷(DOTAP)和胆固醇 3β-N-(二甲氨基乙基)-氨基甲酸酯(DC-chol)组成的阳离子脂质体(DOTAP/DC-chol 脂质体)组成。我们在肺炎链球菌感染的小鼠模型中检查了这种阳离子脂质体基于 PspA 的鼻腔疫苗的效率。用 PspA 和 DOTAP/DC-chol 脂质体鼻内接种可提供针对致死性吸入肺炎链球菌的保护免疫,提高感染小鼠的存活率。此外,用 PspA 和 DOTAP/DC-chol 脂质体鼻内免疫不仅诱导了黏膜和全身部位产生 PspA 特异性 IgA 和 IgG,还引发了 PspA 特异性 Th17 反应,这在通过宿主先天免疫反应控制肺炎链球菌感染方面发挥了关键作用。我们进一步证明,DOTAP/DC-chol 脂质体增强了 PspA 被鼻树突状细胞(DCs)摄取,这可能是诱导针对肺炎链球菌感染的保护性免疫反应的一种机制。这些结果表明,DOTAP/DC-chol 脂质体将成为针对肺炎链球菌感染的血清型非依赖性通用鼻腔疫苗的有效黏膜疫苗系统。